Cluster of Differentiation 20
CD20 (Cluster of Differentiation 20), also known as B‑lymphocyte antigen CD20 or MS4A1, is a 33–37 kDa non‑glycosylated phosphoprotein belonging to the transmembrane 4 domain family A (MS4A) protein family.
It consists of four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops. Both the N‑ and C‑termini are located in the cytoplasm.
The intracellular segments (1–54 aa, 117–141 aa, 243–297 aa) : The C‑terminal region contains multiple phosphorylation sites that regulate B‑cell activation signals.
The transmembrane segments (55–76 aa, 95–116 aa, 142–162 aa, 222–242 aa) ;
Two extracellular loops: a small loop (ECL1) at residues 77–94 and a large loop (ECL2) at residues 163–221.
ECL2 is the core region recognized by antibodies. It contains a critical disulfide bond between Cys167 and Cys183. It also contains the ANPS core motif (residues 170–173), which is the binding site for Rituximab. Ofatumumab binds to ECL1 and the membrane‑proximal region of ECL2.
The CD20 protein shares approximately 75% amino acid sequence identity between human and mouse orthologs. Its transmembrane and cytoplasmic regions are highly conserved. However, the extracellular loop region containing the key antibody epitopes exhibits only 65% sequence identity. Structural analysis indicates that CD20 is a four‑transmembrane protein. The epitopes are mainly distributed in the large extracellular loop (residues 163–187), which contains the critical ¹⁷⁰ANPS¹⁷³ motif. Type I and type II therapeutic antibodies, such as Rituximab and Obinutuzumab, have overlapping but distinct binding sites. These differences affect effector functions such as complement‑dependent cytotoxicity.
CD20 (MS4A1) is a member of the membrane-spanning 4-domain family A. In normal tissues, it is mainly expressed in the B‑cell lineage, starting from the pre‑B cell stage in the bone marrow through peripheral mature B cells and memory B cells, including B‑cell areas in peripheral blood mononuclear cells, spleen, lymph nodes, and tonsils. It is not expressed in hematopoietic stem cells, pro‑B cells, plasma cells, or T cells. Its physiological functions involve regulating B‑cell proliferation, differentiation, and activation. It may act as a calcium channel to enhance B‑cell receptor signaling, supporting the maintenance of immune responses and the regulation of calcium signals. CD20 plays a critical role in B‑cell development, being expressed from the pre‑B cell stage in the bone marrow through the mature B‑cell stage, but not in plasma cells.
B cell activation and differentiation: CD20 is a key factor in B‑cell activation and differentiation. Upon antigen stimulation, CD20 interacts with the membrane‑bound IgM (sIgM) of the B‑cell antigen receptor (BCR), triggering B‑cell activation, proliferation, and differentiation, ultimately leading to the production of specific antibodies against foreign pathogens. In addition, after B‑cell activation, the BCR‑CD20 complex dissociates, and phosphoproteins and calmodulin‑binding proteins are transiently recruited to CD20, thereby participating in intracellular signal transduction.
Regulation of calcium ion flux: CD20 plays an important role in regulating intracellular calcium concentration. It participates in store‑operated calcium entry (SOCE) and enhances intracellular calcium levels through calcium release‑activated calcium (CRAC) channels, which is the primary mechanism by which lymphocytes raise their intracellular calcium concentration.
Regulation of apoptosis: CD20 is also involved in the apoptotic process of B cells by modulating intracellular signaling pathways, thereby maintaining immune system homeostasis. In certain pathological conditions, such as autoimmune diseases or tumorigenesis, the presence of CD20 can help modulate aberrant B‑cell behaviour and maintain immune balance by inducing their apoptosis.
Under pathological conditions, especially in B‑cell‑derived tumours, CD20 expression is generally sustained but its level varies according to tumour type. For example, it is highly expressed in diffuse large B‑cell lymphoma and follicular lymphoma, supporting tumour cell proliferation and survival, whereas it is weakly expressed or negative in chronic lymphocytic leukaemia/small lymphocytic lymphoma, which may lead to resistance to targeted therapies. In non‑B‑cell tumours such as solid tumours, CD20 is often expressed by tumour‑infiltrating B lymphocytes and is associated with antitumour immunity; its high density often predicts a better prognosis, whereas the tumour cells themselves rarely show altered expression. Functionally, CD20 serves as a key target in tumours, facilitating monoclonal antibody (e.g., rituximab)‑mediated complement‑dependent cytotoxicity and antibody‑dependent cell‑mediated cytotoxicity. Aberrant expression can drive resistance mechanisms, such as alternative splicing leading to translational defects. CD20 is also highly expressed in various B‑cell malignancies, including B‑cell lymphomas and chronic lymphocytic leukaemia.
Mosunetuzumab (CD20-TDB) is a fully humanized IgG1 bispecific antibody. It is assembled using the knobs-into-holes technology. Its design principle is to simultaneously bind CD20 and CD3 to induce T cell‑mediated conditional B‑cell killing. The Fc domain is silenced to avoid off‑target effector functions. Affinity parameters include a KD of 40 nM for human CD3ε and 2.5 nM for human CD20. It also shows similar cross‑reactivity to cynomolgus monkey CD3 and CD20, supporting nonclinical evaluation.
In vitro studies were performed using CD20‑expressing B‑cell lines (e.g., BJAB, SU‑DHL‑4, OCI‑Ly10, WSU‑DLCL2) and patient‑derived primary CLL/lymphoma cells (with surface CD20 expression). The experimental formats included T‑cell‑mediated cytotoxicity assays (E:T ratio 1:1–10:1, 4–24 h, with killing assessed by flow cytometry) and T‑cell activation analyses (to verify the mechanism, via CD69/CD25 upregulation and cytokine release detection). Key results showed a killing EC50 of 0.3–5 pM. Mechanistic validation confirmed that the killing was granzyme‑dependent and independent of FasL, and that it induced T‑cell activation, cytokine release, and could be mediated by any T cells regardless of clonal specificity, activation, or differentiation status.
In vivo efficacy evaluation was performed using huNSG mouse xenograft models (BJAB or patient‑derived cell transplantation to model B‑cell malignancies, with humanization achieved via human PBMC or CD34+ HSC engraftment for CD3/CD20 targeting) and huCD20‑huCD3 double transgenic mice (with FACS confirmation that huCD20 expression on mouse B cells and huCD3ε on T cells were comparable to those in healthy humans). Dosing regimens included single or multiple IV doses of 0.005–0.5 mg/kg, and the results showed complete tumour regression and B‑cell depletion (dose‑dependent at 0.05–0.5 mg/kg in the huCD20‑huCD3 model); the primary endpoints included tumour inhibition rate >90% and prolonged survival. In cynomolgus monkey models, a single dose of 1 mg/kg led to B‑cell depletion in peripheral blood and lymphoid tissues, with pharmacokinetic profiles similar to those of conventional monoclonal antibodies.
CD20 is a transmembrane phosphoprotein that is highly expressed on mature B cells and in over 90% of B‑cell non‑Hodgkin lymphomas (NHL) and chronic lymphocytic leukaemia (CLL), correlating with malignant transformation and poor prognosis in these indications, thereby providing a validated therapeutic target with a favourable window due to its very low expression on normal non‑B cells and stem cells, enabling selective depletion through mechanisms including antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), and direct apoptosis. This forms a robust “target‑mechanism‑clinical” closed loop, primarily targeting relapsed/refractory (R/R) patients after chemoimmunotherapy, but also used in first‑line settings in subgroups such as diffuse large B‑cell lymphoma (DLBCL). Approved products include rituximab (FDA approved in 1997 for NHL), ofatumumab, obinutuzumab and their biosimilars, while pipeline candidates such as CD20‑directed CAR‑T (e.g., NCT02710149, NCT04283006) and bispecific antibodies (e.g., mosunetuzumab, plamotamab) are in Phase I–III for R/R B‑cell malignancies. Combination strategies explore synergy with standard chemotherapy (e.g., R‑CHOP), BTK inhibitors (e.g., ibrutinib), immune checkpoint inhibitors (e.g., PD‑1/PD‑L1 blockade to enhance ADCC), and ADCs, with trials such as NCT02737085 showing improved progression‑free survival. Safety profiles include on‑target/off‑tumour toxicities such as B‑cell depletion leading to infections, infusion‑related reactions, and cytokine release syndrome (CRS); management strategies involve steroid/antihistamine premedication, tocilizumab for CRS, and prophylactic antimicrobials, with low neurotoxicity rates in optimised regimens.
The CD20‑targeted therapy market, primarily addressing B‑cell malignancies such as NHL and CLL rather than multiple myeloma, was valued at approximately USD 35.2 billion globally in 2025 and is projected to reach USD 72.1 billion by 2033 (with North America accounting for ~40%, Europe ~30%, and the Asia‑Pacific region showing the fastest growth at a CAGR of ~12%), driven by expanding indications and biosimilar penetration. Related therapies have a CAGR of 9.1% from 2025 to 2031, with overall lymphoma therapies growing from USD 8.52 billion in 2025 to USD 17.75 billion in 2034 (CAGR 8.5%), and CD20 monoclonal antibodies from USD 10.6 billion in 2024 to USD 20.2 billion in 2032. Representative products such as rituximab (Rituxan) are expected to reach peak sales of approximately USD 5.84 billion in 2026, while biosimilars are contributing to cumulative CD20 market sales exceeding USD 150 billion by 2034; obinutuzumab (Gazyva) is projected at about USD 2.0 billion in 2026. Core growth drivers include the unmet need in the R/R population, novel mechanisms such as bispecific antibodies (BsAbs) and CAR‑T synergies, and combination potential with BTK/PD‑1 inhibitors. In terms of industry positioning, major players such as Roche (Genentech), Regeneron, Novartis, Gilead, and Genmab dominate, with notable BD transactions including Genmab’s USD 1.8 billion acquisition of Profound Bio for ADCs and Roche’s collaborations on glofitamab/mosunetuzumab; the competitive landscape encompasses TCEs (e.g., epcoritamab/glofitamab with 2:1 CD20:CD3 binding for superior T‑cell engagement), CAR‑T (e.g., CD20‑directed therapies such as KITE‑363 with dual CD19/CD20 targeting to prevent antigen escape), and ADCs (e.g., polatuzumab vedotin), with technological differentiation through off‑the‑shelf availability, reduced CRS risk, and multi‑antigen strategies. R&D trends emphasise safety optimisation via step‑up dosing and Fc silencing of BsAbs to mitigate CRS, while multi‑target combinations (e.g., CD20/CD19 or CD20/BCMA) are investment hotspots, as evidenced by approximately USD 14.5 billion in Chinese biopharmaceutical R&D in 2021 and rising allogeneic CAR‑T funding.
CD20 occupies a central clinical position in B‑cell malignancies such as non‑Hodgkin lymphoma (NHL), diffuse large B‑cell lymphoma (DLBCL), and chronic lymphocytic leukaemia (CLL), primarily targeting relapsed/refractory (R/R) patients to address the unmet need after chemoimmunotherapy failure, including cases of post‑CAR‑T relapse, antigen loss, and rapid progression. In first‑line therapy, rituximab‑based R‑CHOP remains the standard, but novel agents are being extended to earlier lines. Current treatment modalities include conventional monoclonal antibodies (mAbs, e.g., rituximab and obinutuzumab), antibody–drug conjugates (ADCs), T‑cell engagers (TCEs)/bispecific antibodies (BsAbs, e.g., CD20×CD3 bispecifics), and CAR‑T therapies (predominantly CD19‑directed, with emerging CD20 dual‑targeting). Technologically, mAbs rely on ADCC, CDC, and direct apoptosis; ADCs enable precise cytotoxic delivery; BsAbs offer off‑the‑shelf advantages via T‑cell redirection, reduced CRS risk, and outpatient administration; and dual‑targeting CAR‑T (e.g., KITE‑363/KITE‑753 targeting CD19/CD20) prevents antigen escape and enhances durable responses. Representative enterprises and core products include Roche/Genentech, which leads in mAbs (obinutuzumab) and BsAbs (glofitamab Columvi, mosunetuzumab Lunsumio, with CR rates of ~40–46%, effective post‑CAR‑T); Genmab/AbbVie’s epcoritamab Epkinly (subcutaneous, ORR ~63%, CR ~40%, showing superiority in indirect comparisons to some CAR‑T); Regeneron’s odronextamab (EMA approved, FDA pending); Gilead/Kite’s KITE‑363/KITE‑753 (dual‑targeting CAR‑T, Phase 1 CR rates of 70–79%, with rapid‑manufacturing versions advancing to Phase II/III); and ADC Therapeutics’ loncastuximab tesirine Zynlonta (in LOTIS‑7 combined with glofitamab, ORR 95.5%, CR 90.9%). The competitive strategy of major players focuses on combination therapies (e.g., BsAbs + ADCs/chemotherapy to improve PFS), dual/multi‑target designs (CD20/CD19 or CD20/CD3 2:1 formats for enhanced affinity), and structural innovations (Fc silencing, step‑up dosing to reduce CRS). Differentiation pathways include toxicity management (premedication and tocilizumab optimisation for CRS/ICANS), indication expansion (post‑CAR‑T failure, CNS involvement, patients unfit for first‑line chemotherapy), and regional dynamics (rapid approvals in China/Asia‑Pacific for local BsAbs/CAR‑T). Key BD events include the Genmab/AbbVie collaboration on epcoritamab and Roche’s internal BsAb pipeline; approved products are mainly mAbs and BsAbs, with leading clinical programmes being dual‑targeting CAR‑T and BsAb+ADC combinations, and the competitive landscape is highly concentrated among Roche, AbbVie/Genmab, and Gilead/Kite, with novel mechanisms reshaping R/R standards.
As of the current date, there are 255 active CD20‑targeted therapy pipelines, with monoclonal antibodies predominating, followed by TCEs, bispecifics, and trispecific TCEs; CAR‑T therapies are also numerous, exceeding 80 programmes. Fourteen antibody drugs have been approved or filed for marketing, including 11 mAbs and 3 bispecifics. In terms of targets, single‑target agents are the majority, while common dual‑target combinations include CD3, CD47, and other B‑cell or T‑cell/NK‑cell components in trispecific TCEs or NKCEs. Regarding indications, the current clinical‑stage CD20 antibody pipeline mainly focuses on B‑cell‑related haematological malignancies and autoimmune diseases mediated by B‑cell abnormalities and antibodies, such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis/psoriatic arthritis.
CD20 (cluster of differentiation 20) is a non‑glycosylated tetraspan transmembrane phosphoprotein belonging to the MS4A family, with a molecular weight of 33–37 kDa. It consists of four hydrophobic transmembrane domains, two extracellular loops (a small loop ECL1 at residues 77–94 and a large loop ECL2 at residues 163–221 containing the critical ¹⁷⁰ANPS¹⁷³ motif and the Cys167–Cys183 disulfide bond), and intracellular phosphorylation sites, with both N‑ and C‑termini located in the cytoplasm. The protein is highly restricted to the B‑cell lineage (from pre‑B to mature B and memory B cells), and is not expressed on haematopoietic stem cells, plasma cells, T cells, or other non‑B lineage tissues. It is consistently or aberrantly expressed in B‑cell malignancies (e.g., >90% of NHL, strong expression in DLBCL, and almost invariably positive in FL) and in autoimmune diseases, providing a wide therapeutic window. Its core mechanisms involve regulating B‑cell activation, calcium channel function, and signal transduction, and its clinical validation was established by rituximab (the first anti‑CD20 mAb approved in 1997), with cumulative global sales exceeding tens of billions of US dollars (rituximab’s historical peak exceeded USD 7 billion and remained high after biosimilar penetration), and has expanded to Fc‑optimised mAbs such as obinutuzumab and next‑generation CD20×CD3 T‑cell engagers (TCEs) such as mosunetuzumab, glofitamab, and epcoritamab, several of which have been approved for r/r FL/DLBCL with ORRs of 56–82% and CRs of 40–60%. CD20‑targeted therapies have evolved from traditional Fc‑enhanced mAbs (ADCC/CDC/direct apoptosis) to T‑cell engagers (TCEs, with bispecific platforms such as Knobs‑into‑Holes, DuoBody®, and CrossMab), ADCs, and dual‑targeting CAR‑T (CD19/CD20 to prevent escape), with trispecific antibodies showing potential but not yet mature.